Article

Myasthenia Gravis: Reflections on Past Challenges and Evolving Strategies

Nicholas J. Silvestri, MD, Associate Professor, Department of Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences; Staff Physician, UBMD, Buffalo, New York

Nicholas J. Silvestri, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Argenx; Alexion; Immunovant; UCB

Serve(d) as a speaker or a member of a speakers bureau for: Argenx; Alexion; UCB


 

Nicholas J. Silvestri, MD, recounts a memorable experience with a patient with myasthenia gravis (MG) during early neurology residency, detailing the diagnostic process and initial treatment with standard therapies. Despite the patient's positive response in terms of efficacy, tolerability issues and side effects posed challenges.

Dr Silvestri highlights the evolution in MG treatment, emphasizing the availability of newer, well-tolerated options with proven efficacy, suggesting a more balanced approach between effectiveness and patient safety in contemporary MG management.

Recommended Reading

Evolving Treatment Options for Generalized Myasthenia Gravis
MDedge Neurology
Myasthenia gravis: Finding strength in treatment options
MDedge Neurology
U.S. incidence, prevalence of myasthenia gravis is rising
MDedge Neurology
Clinical Advances in Myasthenia Gravis From AAN 2023
MDedge Neurology
Myasthenia gravis drug gets FDA nod
MDedge Neurology
In myasthenia gravis, antibodies pass open-label tests
MDedge Neurology
U.S. study finds unexpectedly high prevalence of myasthenia gravis
MDedge Neurology
Newly approved myasthenia gravis drug shows sustained benefits in early responders
MDedge Neurology
Novel myasthenia gravis therapies bring opportunities, challenges
MDedge Neurology
Autoimmune Disease Risk May Rise Following Cushing Disease Remission After Surgery
MDedge Neurology